Sanofi-Aventis To Test Dengue Fever Vaccine In Singapore, Vietnam
This article was originally published in PharmAsia News
Executive Summary
France's Sanofi-Aventis says it will expand its clinical trials for a dengue fever vaccine to Singapore and Vietnam as it attempts to get regulatory approval as soon as 2015. The company's vaccine arm, Sanofi Pasteur, already has trials underway in Thailand and the Philippines. The sometimes-fatal disease affects two million people a year, mostly in developing countries. The Sanofi vaccine would be the first for dengue fever if approved. (Click here for more
You may also be interested in...
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.